Alphamab Oncology
HKEX:9966
Intrinsic Value
Alphamab Oncology is an investment holding company. [ Read More ]
The intrinsic value of one Alphamab Oncology stock under the Base Case scenario is 7.13 HKD. Compared to the current market price of 4.41 HKD, Alphamab Oncology is Undervalued by 38%.
Valuation Backtest
Alphamab Oncology
Run backtest to discover the historical profit from buying and selling Alphamab Oncology stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alphamab Oncology
Current Assets | 1.7B |
Cash & Short-Term Investments | 1.6B |
Receivables | 78.2m |
Other Current Assets | 62.9m |
Non-Current Assets | 605.7m |
PP&E | 604.7m |
Other Non-Current Assets | 937k |
Current Liabilities | 261.3m |
Accounts Payable | 19.4m |
Accrued Liabilities | 123.7m |
Other Current Liabilities | 118.1m |
Non-Current Liabilities | 220.3m |
Long-Term Debt | 202.3m |
Other Non-Current Liabilities | 17.9m |
Earnings Waterfall
Alphamab Oncology
Revenue
|
218.8m
CNY
|
Cost of Revenue
|
-55.2m
CNY
|
Gross Profit
|
163.5m
CNY
|
Operating Expenses
|
-362m
CNY
|
Operating Income
|
-198.4m
CNY
|
Other Expenses
|
-12.2m
CNY
|
Net Income
|
-210.6m
CNY
|
Free Cash Flow Analysis
Alphamab Oncology
Profitability Score
Profitability Due Diligence
Alphamab Oncology's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Alphamab Oncology's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Alphamab Oncology's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Alphamab Oncology's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Alphamab Oncology
According to Wall Street analysts, the average 1-year price target for Alphamab Oncology is 10.12 HKD with a low forecast of 5.35 HKD and a high forecast of 21 HKD.
Shareholder Return
Price
Alphamab Oncology
Average Annual Return | -3.44% |
Standard Deviation of Annual Returns | 17.48% |
Max Drawdown | -86% |
Market Capitalization | 4.3B HKD |
Shares Outstanding | 964 844 032 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-12-12. The firm is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The firm has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The firm operates its businesses in both domestic and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Alphamab Oncology stock under the Base Case scenario is 7.13 HKD.
Compared to the current market price of 4.41 HKD, Alphamab Oncology is Undervalued by 38%.